Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 59

Sort by

Sort Order Select

Journal Articles

Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study

Lin Shen, Jing Bao, Lihong Shou, Ying Lu, Qi Zhu, Li Wang, Weili Zhao

Blood (2024) 144 (Supplement 1): 4399.

https://doi.org/10.1182/blood-2024-204547

Published: 2024

Journal Articles

Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

Blood (2024) 144 (Supplement 1): 2171.

https://doi.org/10.1182/blood-2024-212040

Published: 2024

Journal Articles

A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation

Hengwei Wu, Jimin Shi, Yi Luo, Jian Yu, Huarui Fu, Lizhen Liu, Xiaoyu Lai, Luxin Yang, Yishan Ye, Congxiao Zhang, Weijie Cao, Junjie Cao, Xiaojun Xu, Xiaoxia Hu, Ying Lu, He Huang, Yanmin Zhao

Blood (2024) 144 (Supplement 1): 1044.

https://doi.org/10.1182/blood-2024-206823

Published: 2024

Journal Articles

Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)

Chunmei Yang, Ying Lu, Juying Wei, Lihong Shou, Hongyan Tong, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2024-200064

Published: 2024

Journal Articles

Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma

Chunmei Yang, Juying Wei, Ying Lu, Liping Mao, Min Yang, Huafeng Wang, De Zhou, Hongyan Tong, Jie Jin, Wen-Juan Yu

Blood (2024) 144 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2024-203722

Published: 2024

Journal Articles

Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China

Yafang Ma, Xiang Zhang, Jian Hou, Lijing Shen, Fei Li, Fancong Kong, Ying Lu, Guowei Li, Jie Jin, Wenjuan Yu

Blood (2024) 144 (Supplement 1): 4280.

https://doi.org/10.1182/blood-2024-203359

Published: 2024

Journal Articles

Analysis of Risk Factors and Development of a Nomogram Prediction Model for Stem Cell Mobilization Failure in Lymphoma Patients

Qingqing Lin, Peipei Ye, Renzhi Pei, Jie Jin, Ying Lu

Blood (2024) 144 (Supplement 1): 5597.

https://doi.org/10.1182/blood-2024-204577

Published: 2024

Journal Articles

A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study

Tian Zeng, Xiudi Yang, Yi Wang, Dijiong Wu, Weiying Feng, Ying Lu, Huafeng Wang, Jian Huang

Blood (2024) 144 (Supplement 1): 1770.

https://doi.org/10.1182/blood-2024-204525

Published: 2024

Journal Articles

Comparing the Clinical and Genetic Features By Next-Generation Sequencing and RNA Sequencing of Polycythemia Vera and Post-Polycythemia Vera Myelofibrosis Patients

Lingrong Tu, Xiudi Yang, Xiaoqiong Zhu, Ying Lu, Honglan Qian, Jian Huang

Blood (2024) 144 (Supplement 1): 6637.

https://doi.org/10.1182/blood-2024-205374

Published: 2024

Journal Articles

8-Chloro-Adenosine Combined with Homoharringtonine Induces Ferroptosis in Acute Myeloid Leukemia

Liping Xu, Haihui Zhuang, Fenglin Li, Jie Jin, Ying Lu

Blood (2024) 144 (Supplement 1): 6102.

https://doi.org/10.1182/blood-2024-204724

Published: 2024

Journal Articles

ARPC2 Targeting Inhibition Progress the Proliferation Suppression of Acute Myeloid Leukemia through PI3K-AKT Pathway

Chunxiao Chen, Fenglin Li, Ying Lu, Renzhi Pei, Jie Jin, Haihui Zhuang, Shuangyue Li

Blood (2024) 144 (Supplement 1): 6101.

https://doi.org/10.1182/blood-2024-204566

Published: 2024

Journal Articles

Wogonin Induces Apoptosis of Acute Myeloid Leukemia Cells through PI3K/Akt Pathway and Synergies with Venetoclax

Xia Jiang, Youhong Li, Lei Jiang, Renzhi Pei, Jie Jin, Ying Lu

Blood (2024) 144 (Supplement 1): 5803.

https://doi.org/10.1182/blood-2024-204697

Published: 2024

Journal Articles

G Protein-Coupled Receptor 183 Mediates Homoharringtonine Resistance Via NF-Κb Pathway in Acute Myeloid Leukemia

Haihui Zhuang, Fenglin Li, Rongzhen Xu, Renzhi Pei, Jie Jin, Ying Lu

Blood (2024) 144 (Supplement 1): 5793.

https://doi.org/10.1182/blood-2024-204563

Published: 2024

Journal Articles

A Predictive Model for Progression to Overt Primary Myelofibrosis in Early/Prefibrotic Primary Myelofibrosis Patients

Shiwei Hu, Xiudi Yang, Xiaoqiong Zhu, Honglan Qian, Ying Lu, Yanxia Han, Huafeng Wang, Jian Huang

Blood (2024) 144 (Supplement 1): 1782.

https://doi.org/10.1182/blood-2024-204773

Published: 2024

Journal Articles

The Effect and Mechanism of Venetoclax in Combination with SAR405 in Acute Myeloid Leukemia

Youhong Li, Xia Jiang, Lei Jiang, Ying Lu, Jie Jin, Renzhi Pei

Blood (2024) 144 (Supplement 1): 5816.

https://doi.org/10.1182/blood-2024-204758

Published: 2024

Journal Articles

Combined Targeting of SYK and BCL-2 in Acute Myeloid Leukaemia and Mechanism Study

Lili Jin, Xia Jiang, Youhong Li, Lei Jiang, Jie Jin, Ying Lu

Blood (2024) 144 (Supplement 1): 5738.

https://doi.org/10.1182/blood-2024-204796

Published: 2024

Journal Articles

Comparing the Efficacy and Safety of Ruxolitinib in Patients with Lower and Higher Risk Myelofibrosis: A Multi-Center, Single-Arm, Exploratory and Prospective Study

Shiwei Hu, Xiudi Yang, Ying Lu, Gang Zhang, Xianghua Lang, Li Huang, Jian Huang

Blood (2024) 144 (Supplement 1): 1786.

https://doi.org/10.1182/blood-2024-205090

Published: 2024

Journal Articles

Screening and Validation of Natural Product with Anti ETP-ALL Activity Using a Novel ETP-ALL Cell Line

Fenglin Li, Haihui Zhuang, Renzhi Pei, Jie Jin, Ying Lu

Blood (2024) 144 (Supplement 1): 5847.

https://doi.org/10.1182/blood-2024-204632

Published: 2024

Journal Articles

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Blood (2024) 144 (Supplement 1): 836.

https://doi.org/10.1182/blood-2024-208355

Published: 2024

Journal Articles

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Blood (2024) 144 (Supplement 1): 5115.

https://doi.org/10.1182/blood-2024-207186

Published: 2024

NARROW

Orelabrutinib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Who Are Intolerant to Prior Bruton Tyrosine Kinase Inhibitors (BTKi): Updated Results from a Phase 2 Study

Easix Score Predicts Overall Survival and Non-Relapse Mortality in Elderly Patients Undergoing Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation

A Multicenter Randomized Controlled Trial of Low-Dose Ruxolitinib for Gvhd Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplantation

Zanubrutinib in Combination with R-CHOP for Previously Untreated Ｍcd Type of Diffuse Large B-Cell Lymphoma (DLBCL)

Orelabrutinib, Rituximab, and Thiotepa (ORT) in Combination with or without High-Dose Methotrexate in Untreated Primary Central Nervous System Lymphoma

Azacitidine, Homoharringtonine and Cytarabine Combined with Granulocyte Colony-Stimulating Factor As Frontline Treatment for Older Patients with Acute Myeloid Leukemia: A Prospective, Multicenter, Single-Arm Phase III Study in China

Analysis of Risk Factors and Development of a Nomogram Prediction Model for Stem Cell Mobilization Failure in Lymphoma Patients

A Prognostic Model Guiding Treatment Switch for 5-Year Deep Molecular Response in Chronic Myeloid Leukemia Patients Receiving Initial Imatinib: An Extensive, Multi-Center, Retrospective Study

Comparing the Clinical and Genetic Features By Next-Generation Sequencing and RNA Sequencing of Polycythemia Vera and Post-Polycythemia Vera Myelofibrosis Patients

8-Chloro-Adenosine Combined with Homoharringtonine Induces Ferroptosis in Acute Myeloid Leukemia

ARPC2 Targeting Inhibition Progress the Proliferation Suppression of Acute Myeloid Leukemia through PI3K-AKT Pathway

Wogonin Induces Apoptosis of Acute Myeloid Leukemia Cells through PI3K/Akt Pathway and Synergies with Venetoclax

G Protein-Coupled Receptor 183 Mediates Homoharringtonine Resistance Via NF-Κb Pathway in Acute Myeloid Leukemia

A Predictive Model for Progression to Overt Primary Myelofibrosis in Early/Prefibrotic Primary Myelofibrosis Patients

The Effect and Mechanism of Venetoclax in Combination with SAR405 in Acute Myeloid Leukemia

Combined Targeting of SYK and BCL-2 in Acute Myeloid Leukaemia and Mechanism Study

Comparing the Efficacy and Safety of Ruxolitinib in Patients with Lower and Higher Risk Myelofibrosis: A Multi-Center, Single-Arm, Exploratory and Prospective Study

Screening and Validation of Natural Product with Anti ETP-ALL Activity Using a Novel ETP-ALL Cell Line

Venetoclax Combined with Hag Regimen in Newly Diagnosed ETP-ALL: A Prospective, Multicenter, Phase 2 Trial

Efficacy and Safety of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Relapse/Refractory Non-Hodgkin's Lymphoma: Real-World Data in Chinese Population

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only